# Open-label Study on Treatment of Primary Aldosteronism With Everolimus

> **NCT03174171** · PHASE2 · COMPLETED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 12 (actual)

## Conditions studied

- Primary Aldosteronism

## Interventions

- **DRUG:** Everolimus 0.75 mg

## Key facts

- **NCT ID:** NCT03174171
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-22
- **Primary completion:** 2018-06-25
- **Final completion:** 2018-06-25
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03174171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03174171, "Open-label Study on Treatment of Primary Aldosteronism With Everolimus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03174171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*